Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : All About Sun Microsystems -- Ignore unavailable to you. Want to Upgrade?

To: JC Jaros who wrote (29290)	3/22/2000 2:06:00 PM
From: High-Tech East	Read Replies (1) \| Respond to of 64865

<<Look at the history of the first artificial heart patient (Paul Winchell's)>> ... you mean "Jerry Mahoney" ha, ha, ha JC, thanks for the great response (and counsel) ... here's my play on Abiomed ... when ABMD gets approval from the FDA to put their TAH in a human (but before they actually do it the first time), I expect that the words Abiomed and the AbioCor TAH will be known by almost every breathing adult in the western world. Think of it as a news story, not an investment ... not since Jarvik in the early 1980s has anyone attempted this ... and that was before we entered our mass communication society of today ... print stories in the Wall Street Journal, Barron's, New York Times, Washington Post, Chicago Tribune, San Jose Mercury News etc. ... as well as Business Week, Fortune, Forbes, Time, Newsweek, etc. ... plus coverage by NBC, CBS, ABC, CNN, CNBC, Discovery, more PBS etc ... COMBINED WITH ... a stock that only has 10,000,000 (est) shares outstanding, is over 80% closely held, has a very well established, conservative, cautious management and board of directors, a company that already has the only FDA approved heart product on the market (the BVS 5000) ... a company that has been around since 1985 (IPO in 1987) ... a company whose institutional ownership doubled to 18.8% during the quarter ending 12/31/99 and we have some explosive possibilities on the upside. ... most stories will be positive, and some negative and doubtful, but public and investor interest will be there ... watch how this stock moves (up and down on 100,000 shares trading volume per day at 100-200 shares per transaction) on almost nonexisting volume ... I intend to sell 60-80% of my stock into that strength before they actually perform the first TAH transplant at what I expect will be a very high multiple of where it is today. Then, if the AbioCor is a total failure (which I do not expect it to be), I will still have my big gains. ... I see ABMD as almost bullet proof (but very volatile) until they put the first AbioCor in someone ... ... show me I am wrong ... convince me ... Ken Wilson